In diabetics, copeptin levels after AMI predicted MACEs (AMI, stroke, severe congestive HF, or CV death), CV mortality, and overall mortality in unadjusted analysis, while in controls, copeptin predicted MACE. This evidence concerns the gene AVP and stroke disorder.